RBC Capital Maintains Outperform on Mind Medicine, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Mind Medicine (MNMD) and increased the price target from $14 to $15.
February 29, 2024 | 5:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained an Outperform rating on Mind Medicine, with a raised price target from $14 to $15.
The increase in price target by a reputable analyst firm like RBC Capital suggests a strong confidence in Mind Medicine's future performance. This endorsement is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100